Abstract
Goal
The goal of this program is to educate pharmacists about the use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (df) combination tablet for the treatment of HIV infection.
Objectives
At the completion of this program, the reader will be able to:
Describe the pharmacology and pharmacokinetics of elvitegravir/cobicistat/emtricitabine/tenofovir df combination.
Discuss the risks associated with the use of elvitegravir/cobicistat/emtricitabine/tenofovir df combination.
Discuss the potential benefit of elvitegravir/cobicistat/emtricitabine/tenofovir df combination for an individual patient.
Apply the information on the use of elvitegravir/cobicistat/emtricitabine/tenofovir df combination to a case study.
Keywords
Get full access to this article
View all access options for this article.